{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"70.8","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"60.2","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"70.8","value":"0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"70.8","value":"0"},{"groupId":"OG004","lowerLimit":"0.2","upperLimit":"41.3","value":"9.1"},{"groupId":"OG005","lowerLimit":"0.5","upperLimit":"71.6","value":"20.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per RECIST version 1.1. CR: Complete disappearance of all target and non-target lesions with the exception of nodal disease; all target and non-target nodes must decrease to normal size (short axis \\<10 mm); all lesions must be assessed. PR: Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions; all target lesions must be assessed. Non-target PR lesions must be non-progressive disease (PD), where PD is unequivocal progression of pre-existing lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 1 mg as a subcutaneous (SC) administration every 2 weeks (Q2W) for a maximum duration of 10.9 months.","id":"OG000","title":"PF-07209960 1 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 3 mg as a SC administration Q2W for a maximum duration of 5.1 months.","id":"OG001","title":"PF-07209960 3 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 10 mg as a SC administration Q2W for a maximum duration of 3.4 months.","id":"OG002","title":"PF-07209960 10 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 15 mg as a SC administration Q2W for a maximum duration of 5.8 months.","id":"OG003","title":"PF-07209960 15 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.","id":"OG004","title":"PF-07209960 20 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.","id":"OG005","title":"PF-07209960 30 mg SC"}],"paramType":"NUMBER","populationDescription":"Response evaluable set included all participants who received at least one dose of study treatment and had measurable disease at baseline and at least one post baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"From start of the treatment until disease progression or discontinuation from study or death due to any cause, whichever occurred first (maximum up to 14.5 months)","title":"Percentage of Participants With Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}